Barclays
RGNX icon

Barclays’s Regenxbio RGNX Stock Holding History

Barclays’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,800
Closed -$225K – 5578
2026
Q1 		$225K Hold
26,800
– – ﹤0.01% 3616
2025
Q4 		$386K Buy
26,800
+5,400
+25% +$67.3K ﹤0.01% 3994
2025
Q3 		$207K Hold
21,400
– – ﹤0.01% 4273
2025
Q2 		$176K Hold
21,400
– – ﹤0.01% 4359
2025
Q1 		$153K Buy
+21,400
New +$159K ﹤0.01% 4191
2024
Q2 		– Sell
-25,000
Closed -$527K – 5228
2024
Q1 		$527K Buy
+25,000
New +$445K ﹤0.01% 3554
2019
Q1 		– Sell
-5,700
Closed -$239K – 7268
2018
Q4 		$239K Buy
+5,700
New +$334K ﹤0.01% 4456

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Barclays's RGNX Position: Q2 2026 in Review

Barclays reduced its Regenxbio (RGNX) stake by 35% in Q2 2026, selling an estimated $194K and leaving 44,067 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Barclays first reported a position in RGNX in Q4 2015 and has held it in 41 quarters since. The position peaked at $7.65M in Q4 2019. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Barclays held 44,067 shares of Regenxbio worth $528K as of Q2 2026.
  • Barclays sold 23,360 Regenxbio shares in Q2 2026, an estimated $194K.
  • Regenxbio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3189 holding.
  • Barclays first reported a position in Regenxbio in Q4 2015 and has held it in 41 quarters since.
  • Barclays's Regenxbio position peaked at $7.65M in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.